SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

COLL

Collegium Pharmaceutical, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed11d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The ADHD franchise is growing strongly and now represents 36% of revenue, partially offsetting the declining pain portfolio. Monitor whether the pain portfolio erosion accelerates and whether AZSTARYS can sustain prescription growth beyond the initial acquisition quarter. The reaffirmed guidance suggests management sees no material change in full-year expectations.

DirectionNeutral
Confidencehigh
Horizonweeks

Nucynta ER

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already on the market — approved since 2008 (IR) and 2011 (ER)
Next catalyst
None dated

What to watchNucynta ER itself is not a catalyst for COLL. The stock's next binary event is Q3 2026 earnings on November 5, 2026, where the market will focus on guidance for the integrated portfolio including the AZSTARYS acquisition. Investors should watch for Nucynta's ongoing revenue erosion from generic tapentadol, and whether Collegium's ADHD pivot can offset pain-portfolio declines to justify the analyst consensus ~$49 target.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$25.16
T+0 close · Nov 5, 2026 · via day close
Latest settled
−0.83%
T+5 · $24.95
Vs SPY
−4.13%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $25.16entry
  2. T+1 · 11d ago −3.78%α −4.09% · $24.21
  3. T+5 · 5d ago −0.83%α −4.13% · $24.95
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Collegium reported Q3 2026 revenue of $216.3M (up 3% YoY, in line with $216.0M consensus) and adjusted EPS of $1.96 (above the $1.86 consensus, a beat of 5.4%). ADHD franchise grew to 36% of revenue with JORNAY PM up 24% YoY, but the pain portfolio declined 18% YoY. GAAP net income fell to $21.8M from $31.5M a year ago, and adjusted EBITDA declined 9% to $121.6M. Full-year 2026 guidance was reaffirmed.

Key Financial Metrics

EPS (Adj.)
$1.96
est $1.86 · +5.4% · GAAP: $0.60
Revenue
$216.3M
est $216.0M · +0.2% · +3.3% YoY
Rating
beat
Guidance
$825M-$855M
maintained
Gross Margin
57.97%

Key Facts

  • Q3 2026 product revenue $216.3M, up 3% YoY from $209.4M
  • Adjusted EPS $1.96 vs consensus $1.86 (beat by 5.4%)
  • GAAP diluted EPS $0.60 vs $0.84 a year ago
  • JORNAY PM revenue $51.9M, up 24% YoY; AZSTARYS revenue $26.5M in first full quarter under Collegium ownership
  • Pain portfolio revenue $138.0M, down 18% YoY
  • Adjusted EBITDA $121.6M, down 9% YoY from $133.0M
  • Full-year 2026 guidance reaffirmed: product revenue $825-$855M, adjusted EBITDA $445-$470M
  • Announced $50M accelerated share repurchase program in Q3 2026

Financial Impact

Revenue in line with consensus; adjusted EPS beat by $0.10 (5.4%); GAAP net income declined 31% YoY; adjusted EBITDA down 9% YoY

revenueepsadjusted_ebitdagaap_net_income

Segment Breakdown

SegmentRevenueGrowth
JORNAY PM$51.9M+24.0%
AZSTARYS$26.5MNot reported
Pain Portfolio$138.0M-18.0%
Belbuca$57.7M-1.0%
Xtampza ER$45.8M-9.0%
Nucynta Franchise$30.8M-44.0%

Risk Factors

  • Pain portfolio declining 18% YoY with Nucynta franchise down 44%
  • GAAP net income fell 31% YoY due to higher operating expenses and acquisition-related costs
  • Adjusted EBITDA declined 9% YoY despite revenue growth
  • Debt increased to $842.5M in term notes from $571.1M at year-end 2025 due to AZSTARYS acquisition financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396299

Track record

24 reports on COLL

Performance horizon

1 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
  2. Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
  4. Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
  5. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  6. Nov 5, 202611d ago Press Release Neutral 5/10 Viewing Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
  7. Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
  8. Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
  9. Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
  10. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026